SymBio On Radar Of VC Firms And Small Biotechs For Tapping Japan's Specialty Market; Signs With Onconova
This article was originally published in PharmAsia News
Executive Summary
TOKYO - SymBio Pharmaceuticals Ltd. is catching the eyes of small biotechs looking for partners in the Japanese market since gaining approval for its first drug last year. Onconova Therapeutics Inc. tied up with SymBio in Japan and South Korea for the first commercial license of its lead compound, the multikinase inhibitor rigosertib